Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC008 in Inclusion Body Myositis
NCT05721573Phase 3Completed
- Sponsor
- Abcuro
- Start
- Feb 2023
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of ulviprubart in inclusion body myositis (IBM), sponsored by Abcuro. Started Feb 2023; status: completed.
02
Drugs
ulviprubart
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT05721573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05721573.